{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Overall response rate: Defined as the composite endpoint of response to treatment which includes Complete Response (CR), Partial Response (PR), stable disease (SD) as defined in International Response Criteria.\n\nInternational Myeloma Working Group Response Criteria for Multiple Myeloma:\n\nCR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow PR: \\> 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \\>90% or to \\< 200 mg/24 h SD: Not meeting criteria for CR, VGPR, PR, or progressive disease","groups":[{"description":"Fludarabine monophosphate, melphalan, Bortezomib: •Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.\n\n* Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2\n* Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan.","id":"OG000","title":"Fludarabine, Melphalan, Bortezomib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}